A carregar...
Developments in metastatic pancreatic cancer: Is gemcitabine still the standard?
In the past 15 years, we have seen few therapeutic advances for patients with pancreatic cancer, which is the fourth leading cause of cancer-related death in the United States. Currently, only about 6% of patients with advanced disease respond to standard gemcitabine therapy, and median survival is...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Baishideng Publishing Group Co., Limited
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3286136/ https://ncbi.nlm.nih.gov/pubmed/22371633 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v18.i8.736 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|